Surufatinib: all 80 studies that test it
Page 1 of 1. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.
- Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingNCT07609121Phase 2
- Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerNot yet recruitingNCT07469956Phase 2
- Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic CancerRecruitingNCT07436741Phase 3
- Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging SystemNot yet recruitingNCT07279532Phase 2
- Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine NeoplasmsRecruitingNCT07272512Phase 4
- Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07156019Phase 2
- Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerRecruitingNCT07086456Phase 2
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung CancerRecruitingNCT06719700Phase 2
- Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract CancerRecruitingNCT06708858Phase 2
- Endoscopic Retrograde Cholangiopancreatography With Radiofrequency Ablation (ERCP-RFA) Combined With Envafolimab and Surufatinib Sequential Therapy for Unresectable Biliary Tract CarcinomaNot yet recruitingNCT06656559Phase 2
- A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.Not yet recruitingNCT06654947Phase 2
- Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine DifferentiationNot yet recruitingNCT06531291Phase 2
- Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingNCT06414915Phase 2
- A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRADNot yet recruitingNCT06329947Phase 2
- Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract CancerNot yet recruitingNCT06255262Phase 1/2
- Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract CancerNot yet recruitingNCT06134193Phase 2
- A Study of Surufatinib in the Treatment of Advanced Soft Tissue SarcomaNot yet recruitingNCT06110650Not applicable
- Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct AdenocarcinomaRecruitingNCT06092645Phase 2
- Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid CancerRecruitingNCT05989425Phase 2
- A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic CancerRecruitingNCT05969171Phase 2
- A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in OsteosarcomaRecruitingNCT05926492Phase 2
- Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
- The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05839275Phase 1/2
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingNCT05832892Phase 1/2
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/2
- Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerNot yet recruitingNCT05746728Phase 1/2
- Surufatinib and Envafolimab as Second or More-line Therapy in Advanced Soft Tissue Sarcoma PatientsNot yet recruitingNCT05722977Phase 2
- Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCNot yet recruitingNCT05668767Phase 2
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
- Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNot yet recruitingNCT05595889Phase 2
- A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Phase 1/2
- Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsNot yet recruitingNCT05527821Phase 2
- Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
- A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric CancerRecruitingNCT05235906Phase 2
- Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic CancerRecruitingNCT05218889Phase 1/2
- An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast CancerRecruitingNCT05186545Phase 2
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingNCT05165407Phase 2
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
- Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRCRecruitingNCT04653480Phase 2
- Open-Label Surufatinib in European Patients With NETTerminatedNCT04579679Phase 2Results posted
- A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02549937Phase 1/2Results posted
- Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction AdenocarcinomaActive, not recruitingNCT06447636Phase 2
- HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic CholangiocarcinomaActive, not recruitingNCT06239532Phase 2
- A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine TumorsTerminatedNCT06158516Phase 2
- Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic CancerCompletedNCT05908747Phase 2
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
- Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung CancerCompletedNCT05509699Phase 2
- Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian CancerCompletedNCT05494580Phase 1/2
- Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT05481476Phase 2
- Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic CancerCompletedNCT05481463Phase 2
- Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later LineStatus unknownNCT05372198Phase 2
- Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05282433Phase 2
- Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor SamplesStatus unknownNCT05171439Phase 2
- Surufatinib in Patients With Osteosarcoma and Soft Tissue SarcomaActive, not recruitingNCT05106777Phase 2
- Open-label Study of Surufatinib in Japanese PatientsCompletedNCT05077384Phase 1/2
- Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal CancerStatus unknownNCT05030246Phase 2
- Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland CarcinomasStatus unknownNCT05013515Not applicable
- Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung CancerActive, not recruitingNCT05003037Phase 2
- Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung CancerStatus unknownNCT04996771Phase 1/2
- Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal CarcinomaStatus unknownNCT04955886Phase 2
- Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal CancerStatus unknownNCT04929652Phase 1/2
- Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung CancerActive, not recruitingNCT04922658Phase 2
- Surufatinib in Recurrent/Metastatic Head and Neck AdenocarcinomasStatus unknownNCT04910854Phase 2
- Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II StudyStatus unknownNCT04764006Phase 2
- Surufatinib Renal Impairment StudyCompletedNCT04755088Phase 1
- Surufatinib Hepatic Impairment StudyCompletedNCT04755075Phase 1
- Second-line Surufatinib Combined With Chemotherapy in Advanced CRCStatus unknownNCT04734249Phase 2
- Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II StudyStatus unknownNCT04524884Phase 2
- A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
- A Study to Assess the Effect of a Strong CYP3A Inhibitor, on Surufatinib in Healthy SubjectsCompletedNCT04372407Phase 1
- A Study to Assess the Effect of a High Fat Meal on Surufatinib in Healthy SubjectsCompletedNCT04372394Phase 1
- A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma PatientsStatus unknownNCT03873532Phase 2/3
- A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SulfatinibCompletedNCT03627520Early Phase 1
- Study of Surufatinib as Second-line Treatment in Patients With Biliary Tract CarcinomaCompletedNCT02966821Phase 2
- Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid CarcinomaCompletedNCT02614495Phase 2
- Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine TumorsCompletedNCT02589821Phase 3
- Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine TumorsCompletedNCT02588170Phase 3
- A Food Effect Phase I Study of the Sulfatinib in Healthy Subjects (HMPL-012)CompletedNCT02320409Phase 1
- Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine TumorsCompletedNCT02267967Phase 1
- Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid TumorsCompletedNCT02133157Phase 1